Overview

Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:
0

Participant gender:
All

Summary

Study objective is to determine whether Pioglitazone (PGZ) can improve clinical outcomes in hyperglycemic acute ischemic stroke (IS). The rationale for the proposed research is to develop an acute intervention that can improve neurological recovery and decrease mortality and morbidity in high-risk diabetic stroke patients.

Phase:

Phase 1/Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Milton S. Hershey Medical Center

Collaborator:

National Center for Advancing Translational Science (NCATS)

Treatments:

Pioglitazone

Criteria

Inclusion Criteria:

1. Stroke Patients ages 21 and over

2. Blood sugar ≥ 150 mg/dl

3. Study drug treatment should be initiated within 12 hours after time of symptom onset,
if known, or the time last known normal (if time to symptom onset is unknown)

4. MRI or CT proven ischemic stroke

5. Initial NIH SS of ≥ 2

6. Willing and able to provide consent

Exclusion Criteria:

1. Known hypersensitivity to PGZ.

2. Infection at the time of presentation as defined by body temperature > 38 degrees C ,
pneumonia evident on chest X-ray, urinary tract infection (positive tests for
nitrites, leukocyte esterase, and bacteria on urine analysis), other acute infection
per history or current use of antibiotic or antiviral treatment.

3. Active malignancy and / or autoimmune disease requiring treatment.

4. Use of immunomodulatory drugs or chemotherapy.

5. History of stroke or brain injury within the last 90 days prior to presentation.

6. Acute illness within the last 30 days which could have affected the white blood cell
count.

7. Known history of clinically significant hypoglycemia.

8. Patients already taking PGZ.

9. Active liver disease (ALT and /or AST 2.5 times the upper limit of normal, total
bilirubin > 1.2 mg/dl).

10. Acute decompensated heart failure, and/or admission for an acute coronary syndrome,
myocardial infarction (MI), cardiac arrest, coronary artery surgery within the past 3
months and patients with New York Heart association Class III and IV heart failure.

11. History of bladder cancer

12. Pregnant and nursing women.

13. Currently incarcerated patients.